Tadashi Yokoyama

Tadashi Yokoyama

Auto-generated profile, based on publicly available information

Tadashi Yokoyama

Yokoyama Hospital for Gastroenterological Diseases

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2006 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
TKTetsu Kojima
Tetsu Kojima
TWToshiaki Watanabe
Toshiaki Watanabe
KHKEISUKE Hata
KEISUKE Hata
MSMasaru Shinozaki
Masaru Shinozaki
TYTadashi Yokoyama
Tadashi Yokoyama
HNHirokazu Nagawa
Hirokazu Nagawa
Cytomegalovirus (CMV) infection has been reported as an exacerbating factor in inflammatory bowel disease but the relationship between CMV infection and ulcerative colitis (UC) remains unclear. There has been no detailed research to elucidate the clinicopathologic features of CMV infection in UC using surgical specimens. The aim of this study was to investigate the clinicopathologic features of CMV infection in UC patients who had undergone colectomy. Surgical specimens taken from UC patients were examined for CMV infection. The patients were divided into three groups: severe, refractory, and UC-associated dysplasia or cancer according to the operative indications. CMV infection rates were evaluated and a comparison of clinical parameters was made between CMV-positive and CMV-negative patients, and the risk factors for CMV infection were analyzed using multivariate analyses. It was found that 25% of 32 patients were positive for CMV in the severe UC group; 8.3% of 72 patients were positive for CMV in the refractory UC group. None of the 22 patients was positive for CMV in the UC-associated dysplasia or cancer group. The CMV-positive rate in the severe UC group was significantly higher than that in the other groups (p<0.05). Patients' age at the time of operation was higher in the CMV-positive group than in the CMV-negative group among the patients with severe UC (p<0.01), and age at operation was an independent risk factor for CMV infection. CMV is found more frequently in severe UC than refractory UC and UC-associated cancer or dysplasia. Higher age can be a risk factor for CMV infection in patients with severe UC. However, a high steroid dose may not always be a risk factor for CMV infection.

15 January 2007 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
TWToshiaki Watanabe
Toshiaki Watanabe
TKTakashi Kobunai
Takashi Kobunai
ETEtsuko Toda
Etsuko Toda
TKTakamitsu Kanazawa
Takamitsu Kanazawa
YKYoshihiro Kazama
Yoshihiro Kazama
HNHirokazu Nagawa
Hirokazu Nagawa
Purpose: Ulcerative colitis (UC) is associated with a high risk of colorectal cancer. To identify genes that could predict the development of cancer in UC, we conducted a DNA microarray analysis using nonneoplastic rectal mucosa of UC patients. Experimental Design: Gene expression in nonneoplastic mucosa of 53 UC patients were examined. Gene expression profiles were examined using human Genome U133 Plus 2.0 gene chip array (Affymetrix). Among 53 UC patients, 10 had UC-associated cancer (UC-Ca group) whereas 43 did not (UC-NonCa group). Results: By comparing gene expression profiles of nonneoplastic rectal mucosae between the UC-Ca and UC-NonCa groups, we could identify 40 genes that were differentially expressed between two groups. The list of discriminating genes included low-density lipoprotein receptor–related protein (LRP5 and LRP6). Previous studies suggested that LRP5 and LRP6 expression promotes cancer cell proliferation and tumorigenesis and are considered as candidate oncogenes. In the present study, both LRP5 and LRP6 showed significantly higher expression in the UC-Ca group, which suggests the importance of these genes in the development of UC-associated colorectal cancers. With the 40 selected discriminating genes, we did class prediction of the development of colorectal neoplasms in UC patients. Using the k-nearest neighbor method and the support vector machine, we could predict the development of UC-associated neoplasms with an accuracy of 86.8% and 98.1%, respectively. Conclusions: These findings have important implications for the early detection of malignant lesions in UC and may provide directions for future research into the molecular mechanisms of UC-associated cancer.

1 June 2011 in Clinical Colorectal Cancer
Verified
Journal Article
Closed access
TWToshiaki Watanabe
Toshiaki Watanabe
TKTakashi Kobunai
Takashi Kobunai
YYYoko Yamamoto
Yoko Yamamoto
HIHiroki Ikeuchi
Hiroki Ikeuchi
KMKeiji Matsuda
Keiji Matsuda
HNHirokazu Nagawa
Hirokazu Nagawa

1 January 2002 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
YKYuji Kuno
Yuji Kuno
KIKenji Ina
Kenji Ina
TNTsuyoshi Nishiwaki
Tsuyoshi Nishiwaki
TTTomoyuki Tsuzuki
Tomoyuki Tsuzuki
MSMasaaki Shimada
Masaaki Shimada
KKKazuo Kusugami
Kazuo Kusugami

1 May 2017 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
YSYasuo Suzuki
Yasuo Suzuki
MIMitsuo Iida
Mitsuo Iida
HIHiroaki Ito
Hiroaki Ito
HNHaruo Nishino
Haruo Nishino
TOToshihide Ohmori
Toshihide Ohmori
THToshifumi Hibi
Toshifumi Hibi
BackgroundThe noninferiority of pH-dependent release mesalamine (Asacol) once daily (QD) to 3 times daily (TID) administration was investigated.MethodsThis was a phase 3, multicenter, randomized, double-blind, parallel-group, active-control study, with dynamic and stochastic allocation using central registration. Patients with ulcerative colitis in remission (a bloody stool score of 0, and an ulcerative colitis disease activity index of ≤2), received the study drug (Asacol 2.4 g/d) for 48 weeks. The primary efficacy endpoint of the nonrecurrence rate was assessed on the full analysis set. The noninferiority margin was 10%.ResultsSix hundred and four subjects were eligible and were allocated; 603 subjects received the study drug. The full analysis set comprised 602 subjects (QD: 301, TID: 301). Nonrecurrence rates were 88.4% in the QD and 89.6% in the TID. The difference between nonrecurrence rates was −1.3% (95% confidence interval: −6.2, 3.7), confirming noninferiority. No differences in the safety profile were observed between the two treatment groups. On post hoc analysis by integrating the QD and the TID, nonrecurrence rate with a mucosal appearance score of 0 at determination of eligibility was significantly higher than the score of 1. The mean compliance rates were 97.7% in the QD and 98.1% in the TID.ConclusionsQD dosing with Asacol is as effective and safe as TID for maintenance of remission in patients with ulcerative colitis. Additionally, this study indicated that maintaining a good mucosal state is the key for longer maintenance of remission.

31 October 2021 in Intestinal Research
Verified
Journal Article
Open access
PDF file
TKTaku Kobayashi
Taku Kobayashi
HIHiroaki Ito
Hiroaki Ito
TAToshifumi Ashida
Toshifumi Ashida
TYTadashi Yokoyama
Tadashi Yokoyama
MNMasakazu Nagahori
Masakazu Nagahori
THToshifumi Hibi
Toshifumi Hibi
Background/Aims: A subgroup analysis was conducted in Japanese patients with moderate to severe ulcerative colitis (UC) enrolled in the phase 3 VISIBLE 1 study, which evaluated the safety and efficacy of a new vedolizumab subcutaneous (SC) formulation.Methods: Eligible patients received open-label infusions of vedolizumab 300 mg intravenous (IV) at weeks 0 and 2 in the induction phase. Patients with clinical response by complete Mayo score at week 6 entered the double-blind maintenance phase and were randomized to vedolizumab 108 mg SC every 2 weeks, placebo, or vedolizumab 300 mg IV every 8 weeks. The primary endpoint was clinical remission (complete Mayo score ≤ 2 points; no individual subscore > 1 point) at week 52.Results: Of 49 patients who entered the induction phase, 22 out of 49 patients (45%) had clinical response at week 6 and were randomized to vedolizumab 108 mg SC (n = 10), placebo (n = 10), or vedolizumab 300 mg IV (n = 2). At week 52, 4 out of 10 patients (40%) who received vedolizumab SC had clinical remission versus 2 out of 10 patients (20%) who received placebo (difference: 20% [95% confidence interval, –27.9 to 61.8]). Two patients (2/10, 20%) who received vedolizumab SC experienced an injection-site reaction versus none who received placebo.Conclusions: Our results indicate that the efficacy of vedolizumab SC in a subgroup of Japanese patients with UC are similar with those in the overall VISIBLE 1 study population, and with those established with vedolizumab IV. The safety and tolerability of vedolizumab SC were generally similar to that established for vedolizumab IV. (ClinicalTrials.gov ID NCT02611830; EudraCT 2015-000480-14)